A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

NCT02864251 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]